Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy

Young,Shih‑Hao; Wei,Tien‑Hsin; Lin,Chung‑Chi; Chu,Chi‑Jen; Lee,Fa‑Yauh; Yu,May‑Ing; Lu,Rei‑Hwa; Chang,Chiao‑Yu; Yang,Pei‑Ling; Wang,Mei‑Hui; Lin,Han‑Chieh

doi:10.3892/mco.2016.857

Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy

Authors:
- Shih‑Hao Young
- Tien‑Hsin Wei
- Chung‑Chi Lin
- Chi‑Jen Chu
- Fa‑Yauh Lee
- May‑Ing Yu
- Rei‑Hwa Lu
- Chiao‑Yu Chang
- Pei‑Ling Yang
- Mei‑Hui Wang
- Han‑Chieh Lin
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan, R.O.C., Healthcare and Services Center, Taipei Veterans General Hospital, Taipei 11217, Taiwan, R.O.C.
Published online on: April 14, 2016 https://doi.org/10.3892/mco.2016.857
Pages: 165-170

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Reactivation of hepatitis B virus (HBV) infection is common (~20‑50%) during cancer chemotherapy. Baseline HBV replication status is an important risk factor for HBV reactivation. To date, data on the baseline HBV DNA level for chronic hepatitis B (CHB) patients prior to chemotherapy, particularly for non‑hematological malignancies, are limited. a total of 105 consecutive CHB patients with solid tumors who received prophylactic antiviral therapy prior to chemotherapy from November, 2011 to December, 2014, were enrolled in this study. The patients' tumors included: breast cancer (37.1%), lung cancer (18.1%), colon cancer (17.1%), head and neck cancer (10.5%), other gastrointestinal tract malignancies (8.6%), gynecological cancer (4.8%) and others (3.8%). The mean age of the enrolled patients was 55.2±1.1 years, 48 of the patients were male, 3 were hepatitis B e antigen‑positive, and 26.7% had abnormal alanine aminotransferase (ALT) levels at baseline. The median HBV DNA level measured by quantitative polymerase chain reaction assay prior to chemotherapy was 3.30 log10 IU̸ml and 49.5% of the enrolled patients had a baseline HBV DNA level >2,000 IU̸ml. A wide range of HBV distribution was found: <20 IU̸ml (15.2%), 20≤DNA<2,000 IU̸ml (35.3%), 2,000≤DNA<20,000 IU̸ml (26.6%), 20,000≤DNA<106 IU̸ml (17.2%) and <106 IU̸ml (5.7%). Age and baseline ALT level were not strongly associated with virological activity. The mean HBV DNA and the percentage of patients with HBV DNA >2,000 IU̸ml were comparable between different cancer groups. Quantitative HBsAg level was a major determinant of baseline HBV DNA, and a significant correlation was noted between log10 hepatitis B surface antigen and log10 HBV DNA levels (γ=0.641, P<0.001). Our study demonstrated a wide distribution of baseline HBV DNA level among CHB patients diagnosed with non‑hematological malignancies. Of note, approximately half of the patients (i.e., those with HBV DNA >2,000 IU̸ml) had a higher risk of HBV reactivation if no appropriate antiviral prophylaxis was undertaken.

View Figures

View References

1	Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK and Todd D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 100:182–188. 1991.PubMed/NCBI
2	Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B and Johnson PJ: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol. 62:299–307. 2000. View Article : Google Scholar : PubMed/NCBI
3	Yeo W and Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 43:209–220. 2006. View Article : Google Scholar : PubMed/NCBI
4	Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F and Csako G: Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 148:519–528. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hoofnagle JH: Reactivation of hepatitis B. Hepatology. 49(Suppl 5): S156–S165. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hwang JP and Lok AS: Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 11:209–219. 2014. View Article : Google Scholar : PubMed/NCBI
7	Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S and Johnson PJ: Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. J Med Virol. 70:553–561. 2003. View Article : Google Scholar : PubMed/NCBI
8	Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC and Johnson PJ: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 90:1306–1311. 2004. View Article : Google Scholar : PubMed/NCBI
9	Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, et al: Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 37:1320–1328. 2003. View Article : Google Scholar : PubMed/NCBI
10	Yeo W, Chan TC, Leung NM, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS and Chan PK: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 27:605–611. 2009. View Article : Google Scholar : PubMed/NCBI
11	Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A and Liang R: High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 99:2324–2330. 2002. View Article : Google Scholar : PubMed/NCBI
12	Ohishi W and Chayama K: Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin Exp Nephrol. 15:634–640. 2011. View Article : Google Scholar : PubMed/NCBI
13	Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, et al: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 131:59–68. 2006. View Article : Google Scholar : PubMed/NCBI
14	Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxi A and Di Stefano R: Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: Is the serum hepatitis B virus profile reliable? Liver Int. 29:1171–1177. 2009. View Article : Google Scholar : PubMed/NCBI
15	Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S and Liang R: Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 36:702–709. 2002. View Article : Google Scholar : PubMed/NCBI
16	Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R and Liang R: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 125:1742–1749. 2003. View Article : Google Scholar : PubMed/NCBI
17	Rossi G, Pelizzari A, Motta M and Puoti M: Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 115:58–62. 2001. View Article : Google Scholar : PubMed/NCBI
18	Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN and Ho SK: Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 36:1246–1252. 2002. View Article : Google Scholar : PubMed/NCBI
19	Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology. 47:844–853. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lok AS and McMahon B: AASLD practice guidelines chronic hepatitis B: Update 2009. Hepatology. 50:1–36. 2009. View Article : Google Scholar : PubMed/NCBI
21	Lou SC, Pearce SK, Lukaszewska TX, Taylor RE, Williams GT and Leary TP: An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol. 51:59–63. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chevaliez S, Bouvier-Alias M, Laperche S, Hézode C and Pawlotsky JM: Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol. 48:3641–3647. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tur-Kaspa R, Burk RD, Shaul Y and Shafritz DA: Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA. 83:1627–1631. 1986. View Article : Google Scholar : PubMed/NCBI
24	Yun J, Kim JH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS and Im YH: Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 104:559–563. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yeo W and Chan HL: Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol. 28:31–37. 2013. View Article : Google Scholar : PubMed/NCBI
26	Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, Chen PJ and Cheng AL: Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res. 24:3035–3040. 2004.PubMed/NCBI
27	Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM and Ward JW: Centers for Disease Control and Prevention (CDC): Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 57:1–20. 2008.PubMed/NCBI
28	European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012. View Article : Google Scholar : PubMed/NCBI
29	Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int. 6:531–561. 2012. View Article : Google Scholar : PubMed/NCBI
30	Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK and Archimandritis AI: Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 69:1352–1355. 2010. View Article : Google Scholar : PubMed/NCBI
31	Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet. 381:468–475. 2013. View Article : Google Scholar : PubMed/NCBI
32	Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB and Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 49:1503–1514. 2009. View Article : Google Scholar : PubMed/NCBI
33	Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC and Lin TY: Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 18:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
34	Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, Wong BC, Leung N, Kwong YL, Liang R and Lau GK: Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 54:1597–1603. 2005. View Article : Google Scholar : PubMed/NCBI
35	Blumberg BS, Sutnick AI and London WT: Hepatitis and leukemia: Their relation to Australia antigen. Bull N Y Acad Med. 44:1566–1586. 1968.PubMed/NCBI
36	Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, et al: Hepatitis B surface antigen quantification: Why and how to use it in 2011 - a core group report. J Hepatol. 55:1121–1131. 2011. View Article : Google Scholar : PubMed/NCBI
37	Nguyen T, Desmond P and Locarnini S: The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 3(Suppl 1): S5–S15. 2009. View Article : Google Scholar
38	Chen CH, Lee CM, Wang JH, Tung HD, Hung CH and Lu SN: Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol. 16:1213–1218. 2004. View Article : Google Scholar : PubMed/NCBI
39	Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL and Sung JJ: Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 5:1462–1468. 2007. View Article : Google Scholar : PubMed/NCBI